Search results for "enzyme inhibitors"

showing 10 items of 559 documents

Gastrointestinal disturbances and their management in miglustat‐treated patients

2011

Miglustat (Zavesca®) is approved for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease (GD1) for whom enzyme replacement therapy is unsuitable, and for the treatment of progressive neurological manifestations in adult and paediatric patients with Niemann-Pick disease type C (NP-C). Gastrointestinal disturbances such as diarrhoea, flatulence and abdominal pain/discomfort have consistently been reported as the most frequent adverse events associated with miglustat during clinical trials and in real-world clinical practice settings. These adverse events are generally mild or moderate in severity, occurring mostly during the initial weeks of therapy. The mechanis…

AdultLoperamideAbdominal painmedicine.medical_specialty1-DeoxynojirimycinMalabsorptionDrug-Related Side Effects and Adverse ReactionsGastrointestinal DiseasesModels BiologicalGastroenterologyInternal medicineMiglustatGeneticsmedicineHumansEnzyme InhibitorsChildAdverse effectGenetics (clinical)Clinical Trials as TopicGaucher Diseasebusiness.industryEnzyme replacement therapymedicine.diseaseClinical trialEndocrinologymedicine.symptombusinessFlatulencemedicine.drugJournal of Inherited Metabolic Disease
researchProduct

Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial fu…

2010

Endothelium-dependent flow-mediated dilation (FMD) is measured as the increase in diameter of a conduit artery in response to reactive hyperemia, assessed either at a fixed time point [usually 60-s post-cuff deflation (FMD60)] or as the maximal dilation during a 5-min continuous, ECG-gated, measurement (FMDmax-cont). Preliminary evidence suggests that the time between reactive hyperemia and peak dilation (time to FMDmax) may provide an additional index of endothelial health. We measured FMDmax-cont, FMD60, and time to FMDmax in 30 young healthy volunteers, 22 healthy middle-aged adults, 16 smokers, 23 patients with hypertension, 40 patients with coronary artery disease, and 22 patients wit…

AdultMaleAdolescentBrachial ArteryEndotheliumPhysiologyCoronary Artery DiseaseElectrical conduitForearmPhysiology (medical)medicineHumanscardiovascular diseasesEnzyme InhibitorsReactive hyperemiaHeart FailureAnalysis of Variancebusiness.industrySmokingMiddle AgedVasodilationNG-Nitroarginine Methyl Estermedicine.anatomical_structureRegional Blood FlowAnesthesiaHypertensionCirculatory systemcardiovascular systemDilation (morphology)FemaleEndothelium VascularCardiology and Cardiovascular MedicinebusinessBlood vesselArteryAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

V2-receptor–mediated relaxation of human renal arteries in response to desmopressin

1999

The effects of deamino-8-D-arginine vasopressin (desmopressin), a V2 receptor antidiuretic agonist, were studied in isolated rings from branches of renal arteries obtained from 22 patients undergoing nephrectomy. The rings were suspended in organ bath chambers for isometric recording of tension. In precontracted rings with norepinephrine (10(-6) to 3 x 10(-6) mol/L), desmopressin (10(-11) to 3 x 10(-7) mol/L) caused endothelium-dependent relaxation (81%+/-4% reversal of the initial contraction in arteries with endothelium; 20%+/-4% in arteries without endothelium; P < .05). The relaxation to desmopressin in rings with endothelium was reduced significantly by indomethacin (10(-6) mol/L) and …

AdultMaleAgonistReceptors VasopressinVasopressinmedicine.medical_specialtymedicine.drug_classMuscle RelaxationIndomethacinIn Vitro TechniquesRenal AgentsMuscle Smooth VascularRenal ArteryIsometric ContractionArginine vasopressin receptor 2Internal medicineInternal MedicinemedicineHumansCyclooxygenase InhibitorsDeamino Arginine VasopressinEnzyme InhibitorsDesmopressinReceptorAgedVasopressin receptorbusiness.industryAntidiuretic Hormone Receptor AntagonistsMiddle AgedVasodilationNG-Nitroarginine Methyl EsterEndocrinologyCirculatory systemProstaglandinsFemaleNitric Oxide SynthasebusinessAntidiuretic Hormone Receptor Antagonistshormones hormone substitutes and hormone antagonistsmedicine.drugAmerican Journal of Hypertension
researchProduct

Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin

1997

Purpose: The goal of this study was to determine the effects of vasopressin and the selective V 2 -receptor agonist desmopressin on human saphenous veins, with special emphasis on endothelium-mediated responses. Methods: Human saphenous vein segments were obtained from 35 patients undergoing coronary bypass surgery. Paired segments, one normal and the other deendothelized by gentle rubbing, were mounted for isometric recording of tension in organ baths. Concentration-response curves to vasopressin and desmopressin were determined in the presence and in the absence of either the V,-receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 −6 mol/L), the V 1 -V 2 receptor antagonist desGly-d(CH 2 ) 5 D-T…

AdultMaleAgonistReceptors Vasopressinmedicine.medical_specialtyVasopressinVasopressinsmedicine.drug_classVasodilator AgentsIndomethacinVasodilationHormone AntagonistsVasotocinIsometric ContractionInternal medicinemedicineHumansVasoconstrictor AgentsCyclooxygenase InhibitorsDeamino Arginine VasopressinSaphenous VeinEnzyme InhibitorsDesmopressinReceptorAgedDose-Response Relationship Drugbusiness.industryAntagonistMiddle AgedReceptor antagonistArginine VasopressinNG-Nitroarginine Methyl EsterEndocrinologyProstaglandinsFemaleSurgeryEndothelium VascularNitric Oxide Synthasemedicine.symptombusinessCardiology and Cardiovascular MedicineAntidiuretic Hormone Receptor AntagonistsVasoconstrictionhormones hormone substitutes and hormone antagonistsmedicine.drugJournal of Vascular Surgery
researchProduct

Effects of Some Guanidino Compounds on Human Cerebral Arteries

1999

Background and Purpose —Accumulation of endogenous guanidino-substituted analogues of l -arginine in chronic renal failure might contribute to some of the vascular and neurological disorders of this pathology. We tested the hypothesis that in human cerebral arteries, some guanidino compounds may increase vascular tone, through nitric oxide (NO) synthase inhibition, and impair endothelium-dependent relaxation. Methods —Rings of human middle cerebral artery were obtained during autopsy of 26 patients who had died 3 to 12 hours before. The rings were suspended in organ baths for isometric recording of tension. We then studied the responses to N G -monomethyl- l -arginine (L-NMMA), N G , N G -…

AdultMaleMiddle Cerebral Arterymedicine.medical_specialtyEndotheliumVasodilator AgentsCerebral arteriesEndogenyMethylguanidineArginineGuanidinesNitric oxidechemistry.chemical_compoundmedicine.arteryInternal medicinemedicineHumansVasoconstrictor AgentsEnzyme InhibitorsAgedEC50Advanced and Specialized Nursingomega-N-Methylargininebusiness.industryMiddle Agedmedicine.diseaseUremiaSurgeryEndocrinologymedicine.anatomical_structurechemistryMiddle cerebral arteryFemaleNeurology (clinical)Nitric Oxide SynthaseCardiology and Cardiovascular MedicinebusinessAcetylcholinemedicine.drugStroke
researchProduct

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral b…

2001

We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity. In general, STI-571 was well tolerated in this heavily pretreated group of patients with a non-hematologic and hematologic toxicity profile similar to that observed in a previous phase I trial at comparable doses. Five of nine patients with CML in transformation (AP, BC) were evaluable for hematologic response. Two of five patients had transient reductions in WBC and…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentFusion Proteins bcr-ablAntineoplastic AgentsPhiladelphia chromosomeTransplantation AutologousPiperazinesLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansEnzyme InhibitorsChemotherapyABLbusiness.industryHematopoietic Stem Cell Transplantationbreakpoint cluster regionHematologyMiddle AgedProtein-Tyrosine Kinasesmedicine.diseaseCombined Modality TherapyHematologic ResponseBlood Cell CountPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesToxicityImmunologyImatinib MesylateFemaleComplicationbusinessLeukemia
researchProduct

Retinol oxidation to retinoic acid in human thyroid glandular cells.

2014

Abstract Retinoic acid is regarded as the retinol metabolite that controls proliferation and differentiation of epithelial cells. In the present study, we investigated the potential role of xanthine dehydrogenase (XDH) in retinoic acid biosynthesis in human thyroid glandular cells (HTGC). In particular, we observed that cellular retinoids binding proteins (CRBPs) are also implicated in the biosynthetic pathway leading to retinoic acid formation in primary cultures of HTGC, as we have already reported for human mammary epithelial cells (HMEC). After partial protein purification, the enzyme responsible for retinoic acid biosynthesis was identified and quantified as XDH by immunoassay, by its …

AdultMaleXanthine DehydrogenasePrimary Cell CultureRetinoic acidThyroid GlandOxypurinolRetinoic acid receptor betaTretinoinBiologyXanthinechemistry.chemical_compoundBiosynthesisSettore BIO/10 - BiochimicaDrug DiscoveryHumansEnzyme InhibitorsVitamin AEnzyme AssaysPharmacologyImmunoassayRetinolEpithelial CellsRetinol-Binding Proteins CellularGeneral MedicineMiddle AgedXanthineUric AcidRetinoic acid receptorchemistryXanthine dehydrogenaseBiochemistryCRABPs CRBPs human glandular cells. retinoic acid biosynthesis. retinol oxidation xanthine dehydrogenaseUric acidFemaleOxidation-ReductionJournal of enzyme inhibition and medicinal chemistry
researchProduct

Mechanism of Free Radical Production in Exhaustive Exercise in Humans and Rats; Role of Xanthine Oxidase and Protection by Allopurinol

2000

Exhaustive exercise generates free radicals, However, the source of this oxidative damage remains controversial. The aim of this paper was to study further the mechanism of exercise-induced production of free radicals, Testing the hypothesis that xanthine oxidase contributes to the production of free radicals during exercise, me found not only that exercise caused an increase in blood xanthine oxidase activity in rats but also that inhibiting xanthine oxidase with allopurinol prevented exercise-induced oxidation of glutathione in both rats and in humans. Furthermore, inhibiting xanthine oxidase prevented the increases in the plasma activity of cytosolic enzymes (lactate dehydrogenase, aspar…

AdultMaleXanthine OxidaseFree RadicalsAllopurinolPhysical ExertionClinical BiochemistryAllopurinolOxidative phosphorylationallopurinolPharmacologyMitochondrionmedicine.disease_causeBiochemistrychemistry.chemical_compoundphysical exerciseMalondialdehydeGeneticsmedicineoxidative stressAnimalsHumansAspartate AminotransferasesEnzyme InhibitorsRats WistarMuscle SkeletalXanthine oxidaseCreatine KinaseExerciseMolecular BiologyOxidase testL-Lactate DehydrogenaseFree Radical ScavengersCell BiologyGlutathioneXanthineGlutathioneMitochondriaRatsOxidative StressLiverchemistryBiochemistryxanthine oxidaseOxidative stressmedicine.drugIUBMB Life (International Union of Biochemistry and Molecular Biology: Life)
researchProduct

How ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angio…

2009

Abstract Purpose To investigate how genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS) influence hypertension (HT) control with angiotensin-converting enzyme inhibitor drugs (ACEI). Methods A case–control, cross-sectional population-based nested study (n = 1514) included hypertensive patients treated with ACEI drugs, either alone or with other antihypertensive drugs. We differentiated between those who did not control their HT (cases) with those who did (controls). Each group's characteristics were compared to determine the risk of non-controlled HT associated with RAAS polymorphisms by adjusting for different variables. Results rs11571074 obtained an ORa of 5.26 for T…

AdultMalemedicine.medical_specialtyAdolescentPopulationPharmaceutical ScienceAngiotensin-Converting Enzyme InhibitorsPharmacologyYoung AdultPolymorphism (computer science)Internal medicineRenin–angiotensin systemGenotypemedicineHumanseducationAgedAged 80 and overeducation.field_of_studyPolymorphism GeneticHypertension controlbiologybusiness.industryCase-control studyAngiotensin-converting enzymeMiddle AgedEndocrinologyCross-Sectional StudiesCase-Control StudiesACE inhibitorHypertensionbiology.proteinFemalebusinessmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.

2001

To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension.A multicenter, randomised, double-blind parallel group study was performed in Finland, France, the Netherlands, Spain and Sweden. Three-hundred-and-ninety-five men and women in the age range 20-80 years with primary hypertension were randomised to an 8-week double-blind treatment period with either candesartan cilexetil 8-16 mg or enalapril 10-20 mg once daily, with forced dose titration after 4 weeks. Non-invasive ambulatory blood pressure…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureTime Factorsmedicine.medical_treatmentDiastoleTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood PressureAngiotensin Receptor AntagonistsDouble-Blind MethodEnalaprilHeart RateInternal medicineInternal MedicinemedicineHumansProdrugsEnalaprilAntihypertensive AgentsAgedAged 80 and overChemotherapybiologybusiness.industryBiphenyl CompoundsAngiotensin-converting enzymeGeneral MedicineMiddle AgedAngiotensin IICandesartanEndocrinologyTherapeutic EquivalencyACE inhibitorHypertensionbiology.proteinCardiologyBenzimidazolesFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct